However, the effects of TKIs on immune function in patients can contribute to hepatitis B reactivation, including episodes of hepatitis associated with elevated alanine aminotransferase (ALT), increased mortality from liver failure, and the progression of chronic myelogenous leukemia after reduction or discontinuation of TKIs. The gene discussed is GPT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.